things should get rolling soon on this one...even with FDA approval of only 1 of the 5 drugs under evaluation with the FDA this will double or more
some dd
Intellipharmaceutics Reaches Key Milestone As Bigger One Approaches
http://www.biomedreports.com/2011110182447/intellipharmaceutics-...
Loewen, Ondaatje, McCutcheon Limited (LOM)’s analyst Maria Luckevich, M.Sc., MBA followed today's news and immediately issued a price target of $4.75 for IPCI shares along with a "Speculative Buy" rating.
Her report comes on the heels of another report in which the Company's “buy” rating was reaffirmed by equities research analysts at Ladenburg Thalmann in a research note issued to investors earlier in the month. Ladenburg analysts currently have a $7.00 price target on the stock.
Potential FDA approval of Focalin XR®ANDA-STILL PENDING
Now listen to the Q&A session at the end of this recent webcast presentation from IPCI's CFO for the best possible clue as to how close the FDA's approval of Focalin is now as he mentions human trials already set to go and sales commencing by next october...which is also why PAR more than likely gave IPCI $600K cash upfront recently to expand their Focalin licensing agreement with IPCI
http://wsw.com/webcast/jmp14/ipci/
some dd
Intellipharmaceutics Reaches Key Milestone As Bigger One Approaches
http://www.biomedreports.com/2011110182447/intellipharmaceutics-...
Loewen, Ondaatje, McCutcheon Limited (LOM)’s analyst Maria Luckevich, M.Sc., MBA followed today's news and immediately issued a price target of $4.75 for IPCI shares along with a "Speculative Buy" rating.
Her report comes on the heels of another report in which the Company's “buy” rating was reaffirmed by equities research analysts at Ladenburg Thalmann in a research note issued to investors earlier in the month. Ladenburg analysts currently have a $7.00 price target on the stock.
Potential FDA approval of Focalin XR®ANDA-STILL PENDING
Now listen to the Q&A session at the end of this recent webcast presentation from IPCI's CFO for the best possible clue as to how close the FDA's approval of Focalin is now as he mentions human trials already set to go and sales commencing by next october...which is also why PAR more than likely gave IPCI $600K cash upfront recently to expand their Focalin licensing agreement with IPCI
http://wsw.com/webcast/jmp14/ipci/
